---
title: "Innovent Biologics (IVBXF) Receives a Buy from Huatai Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305918997.md"
description: "In a report released yesterday, from Huatai Securities maintained a Buy rating on Innovent Biologics, with a price target of HK$129.54. The company’s shares closed yesterday at HK$85.80.Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$135.90, implying a 58.39% upside from current levels. In a report released on November 2, Bernstein also maintained a Buy rating on the stock with a HK$128.00 price target."
datetime: "2026-11-18T05:05:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305918997.md)
  - [en](https://longbridge.com/en/news/305918997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305918997.md)
generator: "portal-rs"
---

# Innovent Biologics (IVBXF) Receives a Buy from Huatai Securities

In a report released yesterday, from Huatai Securities maintained a Buy rating on Innovent Biologics, with a price target of HK$129.54. The company’s shares closed yesterday at HK$85.80.

Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$135.90, implying a 58.39% upside from current levels. In a report released on November 2, Bernstein also maintained a Buy rating on the stock with a HK$128.00 price target.

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md)
- [Innovent's Zybrivo Receives Positive CHMP Opinion for First-Line Lung Cancer Treatment](https://longbridge.com/en/news/305586235.md)
- [Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List](https://longbridge.com/en/news/305522173.md)
- [UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO  Ophthalmology R&D](https://longbridge.com/en/news/305767362.md)
- [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**